Does Allergen Immunotherapy Alter the Natural Course of Allergic Disorders?

Yang, X.
February 2001
Drugs;Feb2001, Vol. 61 Issue 3, p365
Academic Journal
Allergy in patients with atopy is caused by clinical adverse reactions to environmental antigen, which is often associated with allergen-specific immunoglobulin (Ig)E production. Since allergy reflects an inappropriate immunological reaction, a therapeutic approach related to immunology is likely to actively alter the natural course of allergic disorders. Allergen immunotherapy, known at various times as desensitisation or hyposensitisation, is very recently defined by the World Health Organization as therapeutic vaccines for allergic diseases. At present, it has become a common clinical practice in selected patients for the treatment and prevention of the recurrence of allergic disorders caused by insect venoms and has proven to be effective in changing the course of allergic responses induced by grass and tree pollen, animal hair and dander, house dust mite and mold, as demonstrated by improvement in clinical symptoms, skin prick test and medication scores. Reported effects of allergen immunotherapy on the natural course of allergic disorders include prevention of reaction following re-sting in insect venom allergy; prevention or decrease the rate of the natural progress of allergic rhinitis to asthma; and inhibition of new sensitisation in monosensitised children. Many aspects of the immune responses associated with allergic disorders, including antibody production, cytokine secretion, T cell activation and local inflammatory reactions, are found to be significantly altered during and/or after immunotherapy. Specifically, the ratio of allergen-specific IgG4 to IgG1 correlates well with positive clinical outcome caused by allergen immunotherapy in patients with pollen-allergy. Allergen immunotherapy affects the cytokine profile of allergen-specific T cells and switches T2 type immune responses in patients with atopy towards T0 or T1 type responses. Although the changes in the absolute value of T1 or T2 cytokines appear quite variable, the increase in the ratio of T1/T2 cytokines is very consistent among published reports, especially in the late stage of treatment. Accumulating evidence indicates that appropriate immunotherapy prevents the onset of new sensitisation and prevents the progress of allergic rhinitis to asthma. Although the changes in B cell and T cell responses, especially IgG antibodies and T1/T2 cytokine production, may be the major mechanism underlying the clinical efficacy of allergen immunotherapy and the prevention of the development of allergic phenotypic changes, multiple mechanisms may be involved in the outcome of alteration of the natural course of allergic disorders.


Related Articles

  • Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies. Calderon, M. A.; Demoly, P.; Casale, T.; Akdis, C. A.; Bachert, C.; Bewick, M.; Bilò, B. M.; Bohle, B.; Bonini, S.; Bush, A.; Caimmi, D. P.; Canonica, G. W.; Cardona, V.; Chiriac, A. M.; Cox, L.; Custovic, A.; De Blay, F.; Devillier, P.; Didier, A.; Di Lorenzo, G. // Clinical & Translational Allergy;11/23/2016, Vol. 6, p1 

    Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working...

  • Hotze Medical Team Offers Tips for Allergy Relief amidst Pollen Season.  // Biomedical Market Newsletter;4/14/2011, p207 

    The article focuses on the tips provided by the medical team of Hotze Health & Wellness Center (HHWC) on how to alleviate symptoms of allergy caused by the spring pollen season. According to HHWC founder Steven F. Hotze, HHWC offers sublingual drops immunotherapy to treat allergy patients by...

  • Guía Mexicana de Práctica Clínica de Inmunoterapia 2011. Larenas-Linnemann, Désirée; Ortega-Martell, José Antonio; del Río-Navarro, Blanca; Rodríguez-Pérez, Noel; Arias-Cruz, Alfredo; Estrada, Alan; Becerril-Ángeles, Martín; Pietropaolo-Cienfuegos, Dino R.; de Jesús Ambriz-Moreno, Maria; Báez-Loyola, Carlos; Cossío-Ochoa, Enna; González-Díaz, Sandra Nora; Hidalgo-Castro, Emilia María; Huerta-Hernández, Rosa Elena; Macías-Weinmann, Alejandra; Oyoqui-Flores, Joel; Ston // Revista Alergia de Mexico;2011, Vol. 58 Issue 1, p3 

    Background: Several international guidelines on immunotherapy exist, but they only apply partially in Mexico. The Mexican guideline of immunotherapy dates from 1998. Objectives: To establish clinical recommendations and suggestions for Allergy residents and specialists for skin testing and...

  • Chapter 3: Allergen immunotherapy: Definition, indication, and reactions. Georgy, Mary S.; Saltoun, Carol A. // Allergy & Asthma Proceedings;May/Jun2012 Supplement, Vol. 33, p9 

    Specific allergen immunotherapy is the administration of increasing amounts of specific allergens to which the patient has type I immediate hypersensitivity. It is a disease modifying therapy, indicated for the treatment of allergic rhinitis, allergic asthma, and hymenoptera hypersensitivity....

  • Allergen extract suspension for subcutaneous injection (Alustal; Phostal): a guide to its use for allergen-specific immunotherapy. Keating, Gillian // Drugs & Therapy Perspectives;Jun2015, Vol. 31 Issue 6, p175 

    Alustal and Phostal are injectable suspensions containing allergen extracts adsorbed onto aluminium hydroxide and calcium phosphate gels, respectively. Alustal and Phostal are indicated for use as subcutaneous allergen immunotherapy (SCIT) in children aged ≥5 years and adults who have type...

  • Oral and sublingual peanut immunotherapy is not ready for general use. Greenhawt, Matthew J. // Allergy & Asthma Proceedings;May/Jun2013, Vol. 34 Issue 3, p197 

    Food oral immunotherapy (OIT) is an investigational peanut allergy treatment aimed to achieve specific oral tolerance induction. Allergic children are given titrated oral (or sublingual) doses of their allergen on a daily basis, unlike in subcutaneous immunotherapy (SCIT). OIT is theorized to...

  • Once-daily sublingual allergen-specific immunotherapy improves quality of life in patients with grass pollen-induced allergic rhinoconjunctivitis: a double-blind, randomised study. Rak, Sabina; Yang, William H.; Pedersen, Martin R.; Durham, Stephen R. // Quality of Life Research;Mar2007, Vol. 16 Issue 2, p191 

    The effect of sublingual immunotherapy on quality of life (QoL) was examined in patients with grass pollen-induced rhinoconjunctivitis. Patients (n = 855) were randomised to once-daily grass allergen tablets (2,500; 25,000; or 75,000 SQ-T Phleum pratense extract; GRAZAX or placebo. Treatment was...

  • Allergens for Laboratories Manufactured in the Czech Republic. Kohout, Petr // Czech Business & Trade;2008 Supplement, Issue 6, p19 

    The article offers information on Bonapol AS, which is a manufacturer of natural allergens, designed for laboratories and pharmaceutical production in Czech Republic. Accordingly, the company specialises in pollens of wild Central-European plants, mainly woody species and of some herbs and...

  • Evaluation of effectiveness of specific subcutaneous immunotherapy for patients with allergic rhinitis and asthma. Zandkarimi, M. R.; Hosseini, R. Farid; Jabbari, F.; Panah, H. Raf'at; Ghasemi, R.; Shirkani, A. // Iranian South Medical Journal;May2013, Vol. 16 Issue 2, p110 

    Background: Allergen immunotherapy involves the administration of gradually increasing quantities of specific allergens to patients with IgE-mediated conditions until a dose is reached that is effective in reducing disease severity from natural exposure. This study evaluated the clinical...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics